Impacts of HIV Treatment Regimens on Archived Drug Resistance
Impact of Antiretroviral Therapy (ART) Switch on Archived HIV-1 Drug Resistance in Virally Suppressed Patients: A Prospective Cohort Study
研究概览
详细说明
Aim/objectives: With the aim of determining the impact of antiretroviral regimen and switch on archived HIV-1 drug resistance mutation (DRM), the study's objectives are, to: (a) estimate the prevalence of DRM in virally suppressed HIV infection; (b) assess changes in archived resistance before and after switch; and (c) identify predictors of archived DRM after regimen switch.
Design: A prospective observational study
Setting: All HIV specialist clinic services in Hong Kong
Methods: Adults living with HIV infection on antiretroviral therapy (ART) with full viral suppression who are planned for regimen switch would be recruited. Controls are patients with and without low level viraemia (LLV) not planned for switch, matched by antiretroviral regimen. Blood samples would be collected before switch, shortly and then 2-3 years after switch. Nanopore sequencing would be performed to identify DRM present in HIV-1 proviral DNA. Transcription of relevant clinical record data would be made to contribute to statistical and phylogenetic analyses
Main outcome measures: Change in DRM frequency between baseline and followups at (a) short term and long term; (b) occurrence of virological failure and time to failure; (c) difference in DRM frequency between presence and absence of LLV, and switched and non-switched patients.
Anticipated outcome: The study results would determine if archived resistance clearance would change following ART switch, identify factors associated with persistence of archived resistance, and inform management on the application of proviral DNA testing in clinical practice.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Shui Shan Lee, MD
- 电话号码:+852 22528812
- 邮箱:sslee@cuhk.edu.hk
研究联系人备份
- 姓名:Ngai Sze Wong, PhD
- 电话号码:+852 22528862
- 邮箱:candy_wong@cuhk.edu.hk
学习地点
-
-
Hong Kong
-
Hong Kong、Hong Kong、中国、0000
- 招聘中
- S.H. Ho Research Centre for Infectious Diseases, The Chinese University of Hong Kong
-
接触:
- Shui Shan Lee, MD
- 电话号码:+852 22528812
- 邮箱:sslee@cuhk.edu.hk
-
接触:
- Ngai Sze Wong, PhD
- 电话号码:+852 22528862
- 邮箱:candy_wong@cuhk.edu.hk
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Patients living with HIV who are (a) aged 18 or above, (b) on antiretroviral therapy, (c) has viral load <20 copies/mL at 2 time points for ≥6 months, (d) planning regimen switch.
- Patients for inclusion in the control group meet the same criteria (a) but they are not planned for switch. Controls include patients with low level viremia (LLV) as defined as ≥2 consecutive viral load level between 21 and 200 copies/mL in the preceding 2 years.
Exclusion Criteria:
- Patients living with HIV who (a) are pregnant, (b) have virologic failure, (c) are suffering from concurrent opportunistic infections, (d) are prisoners , (e) are unable to give consent, and (f) have mental illnesses.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Patients on ART planning for regimen switch
virally suppressed with viral undetectable at 2 consecutive timepoints prior to enrolment
|
|
Patients on ART not for regimen switch
with and without low level viraemia prior to enrolment
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportional difference of drug resistance mutation at short term after regimen switch
大体时间:from enrolment to 3-6 months
|
Percentage difference between the prevalence of drug resistance mutation (DRM) detected by proviral DNA testing at baseline and short term (3-6 months) after regimen switch
|
from enrolment to 3-6 months
|
|
Proportional difference of drug resistance mutation at long term after regimen switch
大体时间:From enrolment to 2-3 years after regimen switch
|
Percentage difference between the prevalence of drug resistance mutation (DRM) detected by proviral DNA testing at baseline and long term (2-3 years) after regimen switch
|
From enrolment to 2-3 years after regimen switch
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prevalence of drug resistance mutation
大体时间:at enrolment
|
Percentage of patients on antiretroviral therapy with drug resistance mutation (DRM) detected by proviral DNA testing at baseline
|
at enrolment
|
|
Proportional Difference of drug resistance mutation prevalence between patients with and without by low level viremia
大体时间:at enrolment
|
Percentage difference in the prevalence of drug resistance mutation (DRM) detected by proviral DNA testing between the presence and absence of low level viremia at baseline
|
at enrolment
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prevalence of virologic failure
大体时间:From enrolment to 2-3 years
|
Prevalence of virologic failure in patients on antiretroviral therapy at 2-3 years after enrolment
|
From enrolment to 2-3 years
|
合作者和调查者
调查人员
- 首席研究员:Shui Shan Lee, MD、S.H. Ho Research Centre for Infectious Diseases, The Chinese University of Hong Kong
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- HK HIV archived DRM
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.